Last reviewed · How we verify
NCT07235813
IL-35: A Key Immunosuppressive Driver in Mycosis Fungoides Modulated by Phototherapy
NA trial testing Phototherapy (PUVA or NB-UVB) in Mycosis Fungoides in 16 participants. Completed in 1 October 2025.
6 July 2025
Quick facts
| Lead sponsor | Kasr El Aini Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 1 January 2025 |
| Primary completion | 6 July 2025 |
| Estimated completion | 1 October 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Phototherapy (PUVA or NB-UVB)
Conditions studied
- Mycosis Fungoides — all drugs for Mycosis Fungoides →
Sponsor
Kasr El Aini Hospital
Who can join
18 and older, any sex, with Mycosis Fungoides. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Mycosis fungoides is the most common type of skin lymphoma. It develops when certain white blood cells (T cells) grow abnormally in the skin, causing red, scaly, or itchy patches. The disease is often treated with phototherapy, a light-based treatment that can control symptoms in early stages. This study looked at a protein called interleukin-35 (IL-35), which normally helps regulate the immune system but can also suppress the body's ability to fight cancer. The investigators aimed to determine if IL-35 levels are higher in patients with mycosis fungoides and whether phototherapy can change those levels. The study enrolled 16 patients with mycosis fungoides and compared them to 16 healthy people. Blood samples and small skin biopsies were taken before and after phototherapy. The study found that IL-35 levels were significantly higher in patients than in healthy people. After phototherapy, IL-35 levels dropped back to normal. These results suggest that phototherapy not only treats skin lesions directly but also helps restore immune balance by lowering IL-35. IL-35 may become a useful marker to monitor disease activity and treatment response in patients with mycosis fungoides.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07235813
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mycosis Fungoides
Currently open trials in the same condition.
- NCT07055477 — A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T- · Phase 1 · recruiting
- NCT06716658 — JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas · Phase 2 · recruiting
- NCT06207812 — Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis · recruiting
- NCT05944562 — Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome · Phase 1 · active not recruiting
- NCT06508463 — Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma · Phase 1 · recruiting
Other Kasr El Aini Hospital trials
Trials by the same sponsor.
- NCT07438652 — Effect of Mediterranean vs Paleolithic Diet on RA Activity, Sarcopenia and QOL: 12-Week RCT · NA · recruiting
- NCT07488039 — Labroplasty in Cases of Anterior Shoulder Instability With Subcritical Glenoid Bone Loss · NA · recruiting
- NCT07274280 — Comparative Evaluation of Ambu AuraGain, LarySeal Pro and I-gel in Pediatric Airway Management for Day-Case Surgery Unde · NA · not yet recruiting
- NCT07348146 — Hand-Sewn vs. Stapled Anastomosis in SADI-S: Early Postoperative Complications. · NA · enrolling by invitation
- NCT07077265 — Comparing Two Different Norepinephrine Infusion Rates for Prophylaxis Against Spinal-induced Hypotension in Elderly · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07235813 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kasr El Aini Hospital
- Last refreshed: 19 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07235813.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing